Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hour(s).

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, Merck & Co., Inc., and TESARO, A GSK Company.

Medical Crossfire®: Critical Conversations Between Ovarian Cancer Centers of Excellence and the Community

Release Date: January 31, 2020
Expiration Date: January 31, 2021
Media: Internet - based

Activity Overview

PARP inhibitors have demonstrated marked efficacy in the treatment of patients with ovarian cancer in both upfront maintenance and later-line settings and have transformed treatment of women with ovarian cancer in recent years. Recent trials have also reported promising results with PARP inhibitors in place of single-agent chemotherapy, as well as in combination with VEGF inhibitors and PD-1 inhibitors. Moreover, histologic and molecular testing has also developed in recent years and is important for guiding treatment decision-making in ovarian cancer and for improving outcomes for patients.

Despite these advances and expansion of treatment options, barriers remain to the adoption of available PARP inhibitor therapies and combination strategies in the community setting. These include lack of knowledge of family medical history, awareness of genetic services, financial anxiety or insurance limitations, inadequate coordination of referrals, lack of knowledge of clinical guidelines, among others.

This activity brings key clinical experts in the medical management of ovarian cancer from both academic cancer centers and community-based hospitals together for an in-depth discussion on how to best apply treatment protocols in the community healthcare setting. The expert panel discusses recent practice-changing trial data and places these findings in the context of real-world clinical situations that allows for clinical decision-making in multidisciplinary teams.

Benefits of Participating

  • Hear the experts describe their use of available diagnostic strategies and treatment options for patient with ovarian cancer
  • Review the latest clinical trial evidence for PARP inhibition, anti-angiogenesis, checkpoint blockade and combination strategies to optimize decision making in ovarian cancer and to identify appropriate clinical trials for your patients
  • Learn about barriers to implementing current diagnostic and treatment options for ovarian cancer patients faced by practitioners in the community
  • Apply the latest data to select treatments with the goal of minimizing adverse events and reducing toxicity in patients with ovarian cancer

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca, Merck & Co., Inc., and TESARO, A GSK Company.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Videos” will be available for your reference.
  • In order to receive a CME/CE Certificate, you must complete the activity.
  • Complete the Posttest and the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE Certificate upon completion of these steps.

Target Audience

This educational program is directed toward medical oncologists, gynecologist oncologists, pathologists, radiation oncologists, and surgical oncologists interested in the treatment and management of ovarian cancer. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with ovarian cancer will be invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Choose appropriate diagnostic strategies and treatment options when using PARP inhibitors in clinical practice for the treatment of patients with ovarian cancer
  • Describe the rationale for ongoing trials using PARP inhibitors and combination therapies in earlier stages and heavily pretreated patients with ovarian cancer
  • Evaluate patients eligible for clinical trials and how to optimize patient communication and the referral process, to increase clinical trial enrollment
  • Define and explain adverse events commonly associated with PARP inhibitors to optimize clinical outcomes of ovarian cancer patients

Faculty, Staff, and Planners’ Disclosures


Ursula Matulonis
Ursula Matulonis, MD
Chief, Division of Gynecologic Oncology
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures: Consultant: ImmunoGen, Merck.

Shannon N. Westin
Shannon N. Westin, MD, MPH, FACOG
Associate Professor
Director, Early Drug Development
Gynecologic Oncology and Reproductive Medicine
UT MD Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research Support: AstraZeneca, ArQule, Bayer, Clovis Oncology, GSK, Roche/Genentech, Contiga Pharmaceuticals, Inc, Novartis; Consultant: AstraZeneca, Clovis Oncology, GSK, Roche/Genentech, Merck, Pfizer, Circulogene, Novartis.

Veena John
Veena John, MD
System Head, Gyn Medical Oncology
Monter Cancer Center
Northwell Health
Lake, Success, NY
Assistant Professor
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

Disclosures: no relevant financial relationships with commercial interests to disclose.

Lyndsay J. Willmott
Lyndsay J. Willmott, MD
Assistant Professor
Department of OBGYN
Creighton University
Assistant Professor
Department of OBGYN
University of Arizona, Phoenix

Disclosures: Grant/Research Support: NRG New Investigator Grant; Consultant: Clovis Oncology, Tesaro; Speaker’s Bureau: Clovis Oncology, Tesaro, Merck, AstraZeneca.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician and nurse relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By